Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.58 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.58 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.58 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.58 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.58 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.58 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.58 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.58 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.58 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.58 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.58 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.58 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.58 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.58 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.58 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.58 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.58 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.47 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29826707 | 0.98 | MAPK1 (0.65) | MAPK1KDM4EL3MBTL1NNMTGABRP | |
| SCHEMBL31532 | 0.98 | MAPK1 (0.65) | MAPK1KDM4EL3MBTL1NNMTGABRP | |
| Tetrahydrofuran SCHEMBL28037003 | 0.86 | MAPK1 (0.51) | MAPK1KDM4EL3MBTL1NNMTGABRP | |
| SCHEMBL7362601 | 0.86 | MAPK1 (0.51) | MAPK1KDM4EL3MBTL1NNMTGABRP | |
| SCHEMBL5543060 | 0.84 | MKNK1 (0.65) | MAPK1KDM4EL3MBTL1NNMTGABRP | |
| SCHEMBL2734773 | 0.82 | CDK8 (0.53) | MAPK1KDM4ENNMTGABRPGABRD | |
| Hydrochloric Acid SCHEMBL5591582 | 0.81 | LMNA (0.59) | NNMTGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL2643803 | 0.80 | NNMT (0.56) | MAPK1KDM4EL3MBTL1NNMTGABRP | |
| 6-Aminonicotinamide SCHEMBL25343859 | 0.79 | NNMT (0.85) | KDM4EL3MBTL1NNMTGABRPGABRD | |
| SCHEMBL13914474 | 0.79 | NNMT (0.66) | MAPK1KDM4EL3MBTL1NNMTGABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178765-A1 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2012-07-12 | — | — | US | disclosed |
| WO-2011081280-A2 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2011-07-07 | — | — | WO | disclosed |
| CN-100586927-C | Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase | NOVARTIS AG | 2010-02-03 | — | — | CN | disclosed |
| EP-1073638-B1 | HETEROCYCLICALLY SUBSTITUTED AMIDES, THEIR PRODUCTION AND THEIR USE | ABBOTT GMBH & CO KG (DE) | 2008-07-23 | — | — | EP | disclosed |
| US-20060205772-A1 | Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type I | COPPOLA GARY M | 2006-09-14 | — | — | US | disclosed |
| CN-1741986-A | Amide derivatives and their use as inhibitors of 11-beta hydroxysteroid dehydrogenase | NOVARTIS AG (CH) | 2006-03-01 | — | — | CN | disclosed |
| EP-1590319-A1 | AMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Novartis AG (CH) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004065351-A1 | AMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | NOVARTIS AG (CH) | 2004-08-05 | — | — | WO | disclosed |
| US-20040097508-A1 | Novel heterocyclically substituted amides, their preparation and use | ABBOTT GMBH & CO. KG (DE) | 2004-05-20 | — | — | US | disclosed |
| US-6630493-B1 | Inhibitors of capain enzymes useful for the treatment of ischemias of the heart, the kidney or of central nervous system (e.g. \"stroke\"), inflammations, muscular dystrophy, cataracts of the eyes, Alzheimer's disease etc. | BASF AKTIENGESELLSCHAFT (DE) | 2003-10-07 | — | — | US | disclosed |
| WO-2003013526-A1 | ANTICOAGULANT COMPOUNDS | MERCK & CO. INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| CN-1301255-A | Heterocyclically substituted amides, their production and their use | BASF AG (DE) | 2001-06-27 | — | — | CN | disclosed |
| EP-1073638-A1 | HETEROCYCLICALLY SUBSTITUTED AMIDES, THEIR PRODUCTION AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999054304-A1 | HETEROCYCLICALLY SUBSTITUTED AMIDES, THEIR PRODUCTION AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097508-A1 | Novel heterocyclically substituted amides, their preparation and use | CAPN1, CAPNS1, CAPN2 | GABRP 1023/4885GABRD 1349/4885GABRA1 1983/4885 |
| US-20120178765-A1 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | GCK, GCKR, HK1 | GABRP 3546/4885GABRD 2268/4885GABRA1 3372/4885 |
| US-20060205772-A1 | Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type I | HSD11B1, HSD11B2, CYP11B1 | GABRP 1737/4885GABRD 1313/4885GABRA1 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.